Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strensiq Average Annual Price Of $285,000 Has Room To Grow

Executive Summary

Alexion expects high proportion of hypophosphatasia patients initiating treatment will be infants or young children; sales likely to increase over time because of weight-based dosing.

Advertisement

Related Content

Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel